ATE391186T1 - Gezielte verabreichung von kuenstlichen genen - Google Patents
Gezielte verabreichung von kuenstlichen genenInfo
- Publication number
- ATE391186T1 ATE391186T1 AT00957535T AT00957535T ATE391186T1 AT E391186 T1 ATE391186 T1 AT E391186T1 AT 00957535 T AT00957535 T AT 00957535T AT 00957535 T AT00957535 T AT 00957535T AT E391186 T1 ATE391186 T1 AT E391186T1
- Authority
- AT
- Austria
- Prior art keywords
- targeted administration
- artificial genes
- artificial
- targeted
- gene delivery
- Prior art date
Links
- 108700005078 Synthetic Genes Proteins 0.000 title abstract 2
- 238000001476 gene delivery Methods 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/377,153 US20020064520A1 (en) | 1999-08-19 | 1999-08-19 | Targeted artificial gene delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE391186T1 true ATE391186T1 (de) | 2008-04-15 |
Family
ID=23487987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00957535T ATE391186T1 (de) | 1999-08-19 | 2000-08-18 | Gezielte verabreichung von kuenstlichen genen |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20020064520A1 (de) |
| EP (1) | EP1204761B1 (de) |
| JP (1) | JP2003507348A (de) |
| CN (1) | CN1237179C (de) |
| AT (1) | ATE391186T1 (de) |
| AU (1) | AU6913800A (de) |
| CA (1) | CA2380517A1 (de) |
| DE (1) | DE60038494D1 (de) |
| NZ (1) | NZ517241A (de) |
| WO (1) | WO2001012235A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875448B1 (en) * | 1999-09-03 | 2005-04-05 | Chugai Seiyaku Kabushiki Kaisha | Method of intracellular sustained-release of drug and preparations |
| CA2404737C (en) * | 2000-04-03 | 2010-06-29 | Santen Pharmaceutical Co., Ltd. | Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug |
| WO2003040399A2 (en) * | 2001-11-02 | 2003-05-15 | Intradigm Corporation | Therapeutic methods for nucleic acid delivery vehicles |
| EP1585560A4 (de) * | 2002-07-26 | 2011-03-16 | Mirus Bio Corp | Zuführung von molekülen und komplexen zu säugerzellen in vivo |
| WO2004072289A1 (ja) | 2003-02-17 | 2004-08-26 | Fuso Pharmaceutical Industries, Ltd. | 新規ウイルスベクター |
| EP1559790A1 (de) * | 2004-02-02 | 2005-08-03 | International University Bremen Gmbh | Vesikel zum Abtrennen von Substanzen aus flüssigen Medien |
| WO2006033679A2 (en) | 2004-05-25 | 2006-03-30 | Chimeracore, Inc. | Self-assembling nanoparticle drug delivery system |
| WO2008108776A1 (en) * | 2006-04-07 | 2008-09-12 | Chimeros, Inc. | Compositions and methods for treating b- cell malignancies |
| WO2007127272A2 (en) * | 2006-04-24 | 2007-11-08 | The Cbr Institute For Biomedical Research | Method of producing immunoliposomes and compositions thereof |
| WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
| WO2013009701A2 (en) | 2011-07-08 | 2013-01-17 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| US8865188B2 (en) | 2011-09-09 | 2014-10-21 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
| US11246877B2 (en) * | 2016-05-20 | 2022-02-15 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
| WO2019028250A1 (en) | 2017-08-02 | 2019-02-07 | The University Of Chicago | NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4948590A (en) * | 1987-06-09 | 1990-08-14 | Yale University | Avidin or streptavidin conjugated liposomes |
| US5665577A (en) * | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| WO1992006180A1 (en) * | 1990-10-01 | 1992-04-16 | University Of Connecticut | Targeting viruses and cells for selective internalization by cells |
| US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| AU4690596A (en) * | 1994-12-30 | 1996-07-24 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
| US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
| JP2000509394A (ja) * | 1996-05-01 | 2000-07-25 | アンティバイラルズ インコーポレイテッド | 細胞膜を横切って物質を輸送するためのポリペプチド結合体 |
| WO1998044143A1 (en) * | 1997-04-03 | 1998-10-08 | Genzyme Corporation | Polymer-modified viruses |
| JP2001523089A (ja) * | 1997-04-10 | 2001-11-20 | 南カリフォルニア大学 | 細胞外マトリックス成分に結合する修飾ウイルス表面蛋白質 |
| EP1093519A2 (de) * | 1998-07-09 | 2001-04-25 | The University Of Southern California | Amphiphile peptide abgegleitet vom zytoplasmatischen ende der viralen hüllproteine |
-
1999
- 1999-08-19 US US09/377,153 patent/US20020064520A1/en not_active Abandoned
-
2000
- 2000-08-18 AU AU69138/00A patent/AU6913800A/en not_active Abandoned
- 2000-08-18 CN CNB008146144A patent/CN1237179C/zh not_active Expired - Fee Related
- 2000-08-18 WO PCT/US2000/022619 patent/WO2001012235A2/en not_active Ceased
- 2000-08-18 DE DE60038494T patent/DE60038494D1/de not_active Expired - Lifetime
- 2000-08-18 CA CA002380517A patent/CA2380517A1/en not_active Abandoned
- 2000-08-18 AT AT00957535T patent/ATE391186T1/de not_active IP Right Cessation
- 2000-08-18 NZ NZ517241A patent/NZ517241A/en unknown
- 2000-08-18 EP EP00957535A patent/EP1204761B1/de not_active Expired - Lifetime
- 2000-08-18 JP JP2001516578A patent/JP2003507348A/ja active Pending
-
2007
- 2007-05-02 US US11/800,048 patent/US20080103108A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003507348A (ja) | 2003-02-25 |
| DE60038494D1 (de) | 2008-05-15 |
| EP1204761A2 (de) | 2002-05-15 |
| EP1204761B1 (de) | 2008-04-02 |
| WO2001012235A3 (en) | 2001-05-25 |
| CA2380517A1 (en) | 2001-02-22 |
| CN1237179C (zh) | 2006-01-18 |
| US20020064520A1 (en) | 2002-05-30 |
| NZ517241A (en) | 2004-01-30 |
| CN1420934A (zh) | 2003-05-28 |
| WO2001012235A2 (en) | 2001-02-22 |
| AU6913800A (en) | 2001-03-13 |
| US20080103108A1 (en) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE391186T1 (de) | Gezielte verabreichung von kuenstlichen genen | |
| EP1312679B8 (de) | Rekombinante MVA Viren und deren Verwendung | |
| WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
| FR11C0027I2 (fr) | Virus de l'influenza recombinants pour vaccins et traitement genetique | |
| FR2727689B1 (de) | ||
| DE69914932D1 (de) | Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis | |
| ATE486614T1 (de) | Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie | |
| ATE333284T1 (de) | Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon | |
| KR970700771A (ko) | 비-바이러스 벡터(Non-viral vector) | |
| WO1996041606A3 (en) | Improved pharmaceutical compositions for gene therapy | |
| WO1998039426A3 (en) | Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products | |
| DE69830249D1 (de) | Zielgerichtete liposomen zur verabreichung von genen | |
| WO1998030709A3 (en) | Non-immunogenic prodrugs and selectable markers for use in gene therapy | |
| MXPA03000061A (es) | Manipulacion de virus de arn encadenados negativos mediante redisposicion de sus genes y usos de los mismos. | |
| ATE320270T1 (de) | Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren | |
| EP1149917A3 (de) | Hepatitis B Vektoren für Gentherapie | |
| WO1999047678A3 (en) | Interferon alpha plasmids and delivery systems, and methods of making and using the same | |
| EE200000102A (et) | Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene | |
| RU2004104335A (ru) | Биологически активные пептиды | |
| WO2001024764A3 (en) | Cell targeting compositions and methods of using the same | |
| NZ324157A (en) | Conditionally replicating viral vectors and their use in treating HIV | |
| WO2000006735A8 (en) | Interferon alpha hybrids | |
| ATE391777T1 (de) | Verwendung von prohibitin-rns in krebsbehandlung | |
| WO2003061581A3 (en) | Compositions and methods for regulating rna stability using polypyrimidine tract proteins | |
| DE60013586D1 (de) | Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |